Is Agios Pharmaceuticals, Inc. (AGIO) a Buy, Sell, or Hold?
NASDAQ : AGIO
Agios Pharmaceuticals, Inc.
$36.97 USD
$0.61 (1.68%)
- Volume
- 972.71K
- Average Volume
- 1.08M
- Market Capitalization
- $2.2B
- P/E Ratio
- -5.10
- Dividend Yield
- 0.00%
- Price Target
- $41.00
- Year High
- $46.00
- Year Low
- $22.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.19
Company Overview
NASDAQ
Brian Goff
Biotechnology
Healthcare
AGIO
540
US
USD
Liquidity Metrics
0.03
14.19
13.59
1.93
0.00
Sales & Valuation
$54.03M
33.29
1.96
-5.71
-6.54
Profitability
-$7.12
-$412.78M
-639.84%
-641.38%
-34.11%
-35.66%
P/E Metrics
-5.10
0.03
0.03
Analyst Price Target & Rating
$41.00
$52.00
$32.00
2/5
29 Analysts
-9.83%
Financial Health Scores
15.98
3/9
$776M
$1.18B
$75.88M
-$423.62M
Key Metrics (TTM)
$2.08B
31.56
-4.98
14.19
-34.11%
-41.43%
-19.77%
-17.79%
747 days
Company Executives
| Name | Title |
|---|---|
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development |
| Craig Thompson | Co-Founder |
| Tak Wah Mak FRSC | Co-Founder |
| James William Burns | Chief Legal Officer |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer |
| Shin-San Su | Co-Founder |
| Cecilia Jones | Chief Financial Officer |
| Krishnan Viswanadhan | Chief Strategy & Operations Officer |
| Lewis Clayton Cantley | Co-Founder |
| Brian Goff | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts. ...
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
2026-07-27 13:41:16
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2026-07-23 11:01:23
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
2026-07-22 13:26:11
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
2026-07-21 11:44:05
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock is trading lower after the update on the sickle cell disease program.
Agios Pharma to discontinue sickle cell disease treatment development
2026-07-21 07:07:57
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment, sending its shares down 14% in premarket trading.
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
2026-07-21 07:00:00
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease Safety and tolerability of tebapivat were consistent with prior sickle cell disease trials sNDA for mitapivat, company's foundational PK activator, is under FDA Priority Review in sickle cell disease; PDUFA goal date is November 1, 2026 CAMBRIDGE, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease.
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
2026-07-10 07:35:00
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
2026-07-08 11:36:15
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Frequently Asked Questions
-
What is the current Agios Pharmaceuticals, Inc. (AGIO) stock price?
-
Agios Pharmaceuticals, Inc.(NASDAQ:AGIO) stock price is $36.97 in the last trading session. During the trading session, AGIO stock reached the peak price of $46 while $22.24 was the lowest point it dropped to. The percentage change in AGIO stock occurred in the recent session was 1.68% while the dollar amount for the price change in AGIO stock was $0.61.
-
AGIO's industry and sector of operation?
-
The NASDAQ listed AGIO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AGIO?
-
Sarah Gheuens | Chief Medical Officer and Head of Research & Development
Craig Thompson | Co-Founder
Tak Wah Mak FRSC | Co-Founder
James William Burns | Chief Legal Officer
T. J. Washburn | Vice President, Controller & Principal Accounting Officer -
How many employees does AGIO have?
-
Number of AGIO employees currently stands at 540. AGIO operates from 88 Sidney Street, Cambridge, MA 02139-4169, US.
-
Link for AGIO official website?
-
Official Website of AGIO is: https://www.agios.com
-
How do I contact AGIO?
-
AGIO could be contacted at phone #617 649 8600 and can also be accessed through its website. AGIO operates from 88 Sidney Street, Cambridge, MA 02139-4169, US.
-
How many shares of AGIO are traded daily?
-
The average number of AGIO shares traded daily for last 3 months was 1.08M.
-
What is the market cap of AGIO currently?
-
The market value of AGIO currently stands at $2.2B with its latest stock price at $36.97